- Home
- BDTX vs BANX Comparison
BDTX vs BANX Comparison
Compare BDTX & BANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BDTX | BANX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.9M | 202.4M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BDTX | BANX |
|---|---|---|
| Price | $1.88 | $19.73 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 475.9K | 37.1K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $18.45 |
| 52 Week High | $4.94 | $22.50 |
Technical Indicators
Market Signals| Indicator | BDTX | BANX |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 37.13 |
| Support Level | $1.76 | $19.33 |
| Resistance Level | $1.90 | $20.26 |
| Average True Range (ATR) | 0.08 | 0.45 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 26.09 | 28.92 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
About BANX ArrowMark Financial Corp.
ArrowMark Financial Corp is a non-diversified, closed-end management investment company. The Fund's objective is to provide stockholders with current income, and to a lesser extent capital appreciation. The company's investments in various portfolios such as debt securities, Trust Preferred and Preferred Securities, preferred securities, exchange-traded funds, money market funds and others.